Marissa
Fayer

At DeepLook Medical, the problem is dense tissue. On a mammogram, dense breast tissue looks white. So does a tumor. Roughly 45% of women have it, and for them the standard image is a snowstorm with something hidden inside.

Marissa Fayer runs the company building the software that helps radiologists see through the white. She took DeepLook from concept through FDA clearance and into global commercialization, with distribution partners attached. She also has dense breast tissue herself, which means the product isn't an abstraction. It's a mirror.

That is the headline, but it undersells the size of what she's actually arguing. Fayer's claim is that women's health has been mispriced for a generation. Only about 2% of venture funding goes to it. She does not read that as a tragedy to be mourned. She reads it as a market that has been, in her phrase, systematically underestimated. The fix is not pity. The fix is capital.

She makes this case from real chairs: CEO of an AI diagnostics company, founder of a nonprofit that has reached more than 128,000 women in 12 countries, a partner at a women's-health fund, and a board member at medtech companies. She has been trusted with the microphone at TEDx, the United Nations, and HLTH. Her forthcoming book carries the whole thesis in its title: Undervalued to Unavoidable.

Silicon Valley wants the mythical creature: the billion-dollar, once-in-a-decade, rules-don't-apply unicorn. Fayer wants the animal that actually exists. Her line is that 99% of companies are not unicorns, but they're the ones propping up the economy. The useful zebra is profitable, sustainable, and it makes a radiologist's day a little less awful. That, she argues, is worth more than chasing a creature most founders will never catch.

The discipline shows in how she got DeepLook cleared. Rather than waving AI at the FDA and hoping, her team started with deterministic, understandable code, the kind a regulator can actually read and follow, before layering in the machine learning. She leveraged predicate devices where they existed. She insisted on testing across diverse populations even where the rules didn't demand it. Clearance came not from cleverness but from legibility.

And she is honest about the parts she hates. Fundraising, she says flatly, is the bane of her existence. She does it anyway, by refusing to pitch only to the small femtech crowd and instead arguing the broader economic case to investors who hadn't thought of women's health as a category at all. Show progress, not polish. Build the zebra. Make the white visible.